Plain-English translation of NCT05565209 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →This is a registry study that follows patients who have received a special device implanted in their heart to prevent strokes caused by atrial fibrillation. The device closes off a small pouch in the heart called the left atrial appendage, which can trap blood clots in people with irregular heartbeats. Researchers want to understand how well this treatment works over the long term—5 years after the procedure.
People with atrial fibrillation (an irregular heartbeat) are at high risk of developing blood clots that can cause strokes. While blood-thinning medications are the first line of treatment, some patients cannot take these drugs safely due to allergies, bleeding risks, or other medical conditions. This study exists to confirm that the heart device is a safe and effective alternative for protecting these high-risk patients.
You likely qualify if…
You likely don't qualify if…
If you are selected, researchers will collect information about you through medical exams and by reviewing your medical records—both before and after your procedure. Some participants will be enrolled as the study begins (prospective arm), while others may already have had the procedure at this hospital and will be included retrospectively. Follow-up visits will occur over 5 years to track your health outcomes, heart imaging results, and any complications.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
France
Assistance Publique - Hôpitaux de Paris
Enrollment target
~250 participants
Started
September 2022
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Emmanuel Teiger, MD, PhD
Assistance Publique - Hôpitaux de Paris
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.